The global penicillin market is anticipated to witness impressive growth during the forecast period. This can be ascribed to the high prevalence of infectious diseases such as lower respiratory infections, malaria, and tuberculosis, among others. In 2020, Africa had the highest prevalence of tuberculosis incidence per 100 000 population. The incidence rate was about 220. Similarly, the Americas reported some 29 new cases of tuberculosis per 100,000 inhabitants. Additionally, growing initiatives and investments by government organizations and pharmaceutical & biotechnology companies across the globe for developing novel antibiotics have significantly increased the demand for penicillin worldwide. Additionally, the growing adoption of new drugs in the healthcare sector has significantly increased, thereby supporting the growth of global penicillin market. Besides, increasing awareness about novel treatments will further increase the demand for penicillin in the coming years, thereby supporting market growth.


Growing Prevalence of Various Types of Infections
Every day the frequency of bacterial infections is increasing. The main reason for increasing bacterial infection is not maintaining proper health, not washing hands before eating or cooking, sneezing without covering, and poor sanitation and hygiene practices. This has significantly increased the demand for antibiotics, thereby creating lucrative growth opportunities for the penicillin market during the forecast period. In 2021, the daily defined dose of antibiotics consumption in Italy was around 13 per 1,000 inhabitants. Similarly, in low and middle-income countries, public transport is the main source of communication, and most of the spread of bacterial infections is being witnessed due to the use of public transport, thereby increasing the demand for antibiotics and creating opportunities for the growth of the penicillin market.


Expanding Research & Development Activities
The growing incidence of antibiotic resistance in bacteria and the increasing prevalence of various communicable bacterial infections have made biotechnology and pharmaceutical companies focus on developing new and advanced therapies and products. This, in turn, is expected to create new prospects for the growth of the penicillin market. According to clinicaltrials.gov, there are around 93 clinical trials related to penicillin that are under different phases. Similarly, betterment in the new drug approval process is expected to boost market growth over the years. In 2020, Merck received an acceptance for a review of a supplemental new drug application from the U.S. FDA for RECARBRIO intended for HABP/VABP. The growing burden of infectious diseases is compelling government and non-government organizations to invest in research and development activities that will further boost the development of novel antibiotics and create new policies for the development of new drugs.



Market Segmentation
The global penicillin market can be segmented by product, type, route of administration, end-user, and by region. Based on the product, the market can be divided into Bulk and Dosage. Based on type, the market can be segmented into Aminopenicillin, Antipseudomonal Penicillin, Beta Lactamase Inhibitor, and Others. Based on the route of administration, the market can be differentiated into Oral, Intramuscular, and Intravenous. Based on end users, the market can be grouped into Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, and Academic & Research Institutions. Regionally, North America dominated the market among Asia Pacific, Europe, the Middle East & Africa, and South America. Among the different countries, the United States dominated the global penicillin market on account of the increasing prevalence of infectious in the country. According to the Centers for Disease Control and Prevention, the number of visits to physician offices for infectious and parasitic diseases is around 7.2 million.


Recent Development
• In August 2022, PAION AG launched XERAVA (eravacycline), in Germany, for the treatment of complicated intra-abdominal infections (cIAI) in adults.

• In October 2021, the Cephalosporin antibiotics branch of GSK was purchased by Novartis. It is currently the exclusive owner of three well-known brands in more than 100 markets, establishing its position as the top manufacturer of antibiotics across the globe.



Market Players
Astellas Pharma Inc., Novartis International AG, GlaxoSmithKline plc, Pfizer Inc., Merck Co. & Inc., F.Hoffmann-La Roche Ltd., Toyama Chemical Co., Ltd., Sanofi Aventis SA, MiddleBrook Pharmaceuticals, Inc., Gilead Sciences Inc. are some of the leading players operating in the Global Penicillin Market.

Report Scope:
In this report, global penicillin market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:
• Penicillin Market, By Product:
  –Bulk
  –Dosage
• Penicillin Market, By Type:
  –Aminopenicillin
  –Antipseudomonal Penicillin
  –Beta Lactamase Inhibitor
  –Others
• Penicillin Market, By Route of Administration:
  –Oral
  –Intramuscular
  –Intravenous
• Penicillin Market, By Route of End User:
  –Hospitals & Clinics
  –Pharmaceutical & Biotechnology Companies
  –Academic & Research Institutions
• Penicillin Market, By Region:
  –North America
   · United States
   · Canada
   · Mexico
  –Europe
   · France
   · Germany
   · United Kingdom
   · Italy
   · Spain
  –Asia Pacific
   · China
   · India
   · Japan
   · South Korea
   · Australia
  –South America
   · Brazil
   · Argentina
   · Colombia
  –Middle East & Africa
   · South Africa
   · Saudi Arabia
   · UAE

Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Penicillin Market.


Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information
• Detailed analysis and profiling of additional market players (up to five).